Reaction

Varicella Zoster Virus Infection reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 2,038 reports · 90 co-occurring drugs

As of the last recalculation, Varicella Zoster Virus Infection appears in 2,038 FAERS reports alongside 90 co-occurring drug terms. The strongest observed disproportionality signal is ALEMTUZUMAB (PRR 60.2).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Alemtuzumab	108	60.2	60.5
Mycophenolate Mofetil	522	52.4	52.6
Mycophenolate Mofetil Hydrochloride	522	52.3	52.5
Busulfan	68	45.6	45.8
Fludarabine Phosphate	151	42.3	42.4
Tacrolimus Ointment 0.1%	381	38.2	38.3
Tacrolimus Extended-Release Capsules	381	38.1	38.2
Thiotepa	34	37.0	37.1
Valganciclovir Hydrochloride Powder,	40	34.1	34.3
Mycophenilic Acid	66	33.6	33.7
Melphalan	69	32.0	32.1
Anakinra	50	31.5	31.6
Tacrolimus	393	31.5	31.6
Ganciclovir	29	29.3	29.4
Basiliximab	33	29.1	29.2
Melphalan Hydrochloride	69	29.1	29.1
Ganciclovir Sodium	29	28.4	28.5
Bendamustine Hcl	42	28.2	28.3
Sirolimus	36	27.8	27.8
Valganciclovir	50	27.7	27.8
Valganciclovir Hydrochloride	50	27.7	27.8
Prednisolone	387	26.8	26.9
Prednisolone Oral	387	26.8	26.9
Prednisolone Oral Solution	387	26.8	26.9
Adalimumab-Fkjp	112	26.1	26.1
Mycophenolic Acid	78	25.8	25.9
Adalimumab-Aaty	112	25.5	25.6
Polatuzumab Vedotin	23	24.3	24.4
Amphotericin B	29	24.0	24.0
Canakinumab	25	23.9	23.9
Adalimumab-Adaz	112	22.9	22.9
Thalidomide	74	21.3	21.4
Methylprednisolone	235	19.5	19.5
Micafungin Sodium	16	19.4	19.5
Cyclophosphamide Injection, Solution	274	18.1	18.1
Cyclophosphamide	274	18.1	18.1
Cyclophosphamide For Injection	274	18.1	18.1
Everolimus Tablets	28	17.3	17.3
Baricitinib	16	17.1	17.1
Itraconazole	18	15.9	15.9
Acyclovir	160	15.4	15.5
Bendamustine Hydrochloride	17	14.6	14.6
Cyclosporine	138	13.5	13.5
Azathioprine	108	13.2	13.2
Anti-Thymocyte Globulin (Rabbit)	10	12.7	12.7
Tofacitinib Citrate	16	12.6	12.6
Rituximab	231	12.5	12.5
Etoposide	81	11.7	11.7
Indomethacin	14	10.9	10.9
Prednisone	423	10.6	10.6
Piperacillin Sodium,Tazobactam Sodium	27	10.5	10.5
Obinutuzumab	16	10.0	10.0
Valacyclovir	40	10.0	10.0
Piperacillin And Tazobactam	12	9.6	9.6
Doxorubicin	80	9.5	9.5
Hydroxychloroquine	67	9.4	9.5
Posaconazole Delayed-Release	10	9.3	9.3
Febuxostat Tablets 40 Mg	9	9.1	9.1
Febuxostat Tablets 80 Mg	9	9.1	9.1
Ifosfamide	17	8.1	8.1
Cytarabine	46	8.0	8.0
Bleomycin Sulfate	8	7.9	7.9
Ursosiol	15	7.9	7.9
Vincristine Sulfate	22	7.7	7.7
Atovaquone	6	7.6	7.6
Budesonide	43	7.6	7.6
Imatinib	13	7.6	7.6
Ursodiol	15	7.1	7.1
Posaconazole	11	6.9	7.0
Ceftriaxone	22	6.9	6.9
Pegaspargase	8	6.7	6.7
Valacyclovir Hydrochloride	45	6.6	6.7
Sumatriptan Succinate	16	6.5	6.5
Ceftriaxone Sodium	23	6.2	6.2
Filgrastim	22	6.0	6.0
Fingolimod Hcl	49	5.9	5.9
Everolimus	29	5.9	5.9
Cisplatin	43	5.7	5.7
Ocrelizumab	33	5.5	5.5
Bortezomib	47	5.5	5.5
Ruxolitinib	35	5.1	5.1
Daratumumab	19	4.9	4.9
Doxorubicin Hydrochloride	15	4.7	4.7
Upadacitinib	33	4.2	4.2
Blinatumomab	4	3.9	3.9
Belimumab	12	3.9	3.9
Ustekinumab	38	3.8	3.8
Siponimod	3	3.4	3.4
Ixekizumab	11	3.0	3.0
Emtricitabine And Tenofovir Alafenamide	3	2.7	2.7

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.